Syntara Past Earnings Performance

Past criteria checks 0/6

Syntara has been growing earnings at an average annual rate of 13.9%, while the Pharmaceuticals industry saw earnings growing at 35.4% annually. Revenues have been declining at an average rate of 2.9% per year.

Key information

13.9%

Earnings growth rate

32.8%

EPS growth rate

Pharmaceuticals Industry Growth31.2%
Revenue growth rate-2.9%
Return on equity-292.0%
Net Margin-237.1%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Improved Revenues Required Before Syntara Limited (ASX:SNT) Stock's 36% Jump Looks Justified

Jul 05
Improved Revenues Required Before Syntara Limited (ASX:SNT) Stock's 36% Jump Looks Justified

Syntara Limited (ASX:SNT) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough

Apr 29
Syntara Limited (ASX:SNT) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough

Syntara Limited's (ASX:SNT) Low P/S No Reason For Excitement

Mar 14
Syntara Limited's (ASX:SNT) Low P/S No Reason For Excitement

We're Hopeful That Pharmaxis (ASX:PXS) Will Use Its Cash Wisely

Feb 28
We're Hopeful That Pharmaxis (ASX:PXS) Will Use Its Cash Wisely

Shareholders May Not Be So Generous With Pharmaxis Ltd's (ASX:PXS) CEO Compensation And Here's Why

Oct 27
Shareholders May Not Be So Generous With Pharmaxis Ltd's (ASX:PXS) CEO Compensation And Here's Why

Key Things To Understand About Pharmaxis' (ASX:PXS) CEO Pay Cheque

Mar 01
Key Things To Understand About Pharmaxis' (ASX:PXS) CEO Pay Cheque

We Think Pharmaxis (ASX:PXS) Can Afford To Drive Business Growth

Jan 04
We Think Pharmaxis (ASX:PXS) Can Afford To Drive Business Growth

Revenue & Expenses Breakdown

How Syntara makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:SNT Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 246-14100
31 Mar 2419-10170
31 Dec 2319-11160
30 Sep 2312-18160
30 Jun 236-1390
31 Mar 23182150
31 Dec 228-2120
30 Sep 22182150
30 Jun 2216-2150
31 Mar 2214-16150
31 Dec 2119-12150
30 Sep 2128-1160
30 Jun 2124-3160
31 Mar 21275166
31 Dec 2022-416-2
30 Sep 2012-13166
30 Jun 2013-14160
31 Mar 2013-21177
31 Dec 1913-18177
30 Sep 1913-18167
30 Jun 1912-20179
31 Mar 197-27179
31 Dec 1822-12179
30 Sep 1821-221710
30 Jun 184961610
31 Mar 1851101613
31 Dec 1737-11613
30 Sep 173671513
30 Jun 179-181515
31 Mar 178-161513
31 Dec 167-161514
30 Sep 168-141516
30 Jun 1610-161515
31 Mar 1647161617
31 Dec 1548141715
30 Sep 1549211915
30 Jun 1547182113
31 Mar 155-341322
31 Dec 148-382512
30 Sep 145-511617
30 Jun 149-52287
31 Mar 145-441816
31 Dec 136-432513

Quality Earnings: SNT is currently unprofitable.

Growing Profit Margin: SNT is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SNT is unprofitable, but has reduced losses over the past 5 years at a rate of 13.9% per year.

Accelerating Growth: Unable to compare SNT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SNT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (46.5%).


Return on Equity

High ROE: SNT has a negative Return on Equity (-292.01%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies